Introduction
Conventional myeloablative hematopoietic cell transplantation (HCT) is associated with significant TRM and mortality, and therefore often limited to younger patients with good clinical status and organ function. Non-myeloablative or reduced-intensity preparative regimens reduce toxicity and risk of TRM, allowing more patients to undergo allogeneic HCT that would otherwise not be suitable for traditional transplantation. Fludarabine (9-b-D-arabinofuranosyl-2-fluoroadenine monophosphate), a purine analog with potent antitumor and immunosuppressive activity, is a common component of conditioning regimens before allogeneic nonmyeloablative HCT. [1] [2] [3] Its immunosuppressive properties promote engraftment, development of mixed chimerism and graft-vs-leukemia effects; however, whether fludarabine exposure levels influence engraftment, GVHD or TRM remains unclear. [4] [5] [6] Fludarabine phosphate is a prodrug that undergoes rapid dephosphorylation to the systemically circulating compound, F-ara-A. F-ara-A is then phosphorylated intracellularly by several kinases to the active 9-b-D-arabinofuranosyl-2-fluoroadenine triphosphate, which is ultimately responsible for the inhibition of DNA synthesis and RNA production, ultimately resulting in apoptosis. [2] [3] 7 The pharmacokinetics of fludarabine has been studied extensively in several disease states but limited data exists in HCT. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Fludarabine pharmacokinetics in nonmyeloablative HCT was evaluated when combined with BU at doses of 30 mg/m 2 were administered daily over 4 days. [19] [20] In these reports, sample sizes were limited and the relationship between F-ara-A pharmacokinetics and clinical outcomes such as engraftment and toxicity were not evaluated. [19] [20] Therefore, the goal of our study was to evaluate the relationship between fludarabine pharmacokinetics and engraftment, acute GVHD, TRM and survival.
Patients and methods

Patients
This was a single center, pharmacokinetic-pharmacodynamic study of fludarabine in 87 patients who underwent allogeneic nonmyeloablative HCT. Patients were eligible to participate if they met protocol eligibility criteria for transplantation and were to undergo a related or unrelated nonmyeloablative allogeneic HCT containing fludarabine, CY and TBI along with CYA and mycophenolate mofetil for post-transplant immunosuppression. This study was approved by the Institutional Review Board and the Cancer Protocol Review Committee. All patients provided written informed consent.
Preparative regimen and immunosuppression
The preparative regimen consisted of cyclophosphamide 50 mg/kg/day i.v. day -6 (total dose 50 mg/kg); fludarabine 40 mg/m Intravenous mycophenolate mofetil and CYA was started on day À3 and converted to oral as tolerated. CYA doses were adjusted to maintain whole blood troughs of 200-400 ng/mL.
Fludarabine pharmacokinetics F-ara-A pharmacokinetic sampling was prospectively carried out with the first dose of fludarabine. Fludarabine was administered i.v. over 1 h at a constant rate and samples were obtained at times 0, 1.6 (100 min), 2, 3, 4, 6, 8, 12 and 24 h after the start of infusion. On the day of transplant a sample was obtained before stem cell infusion. In all, 5 mL of blood was collected at each sampling time and placed in a heparinized green-top tube for F-ara-A analysis. All samples, within 60 min of collection, were centrifuged at 3400 rpm for 10 min at 41C, and the plasma was removed and stored at À801C until analysis. Plasma serum creatinine (SCr) was obtained on day of pharmacokinetics and creatinine clearance (CrCl) estimated by the Cockcroft and Gault equation using ideal body weight. 21 Bioanalysis Detection and quantification of plasma F-ara-A was carried out with HPLC-UV at 267 nm (Agilent Technologies, Wilmington, DE, USA). The chromatographic separation was carried out with a Phenomenex Polar-RP, 4.6 Â 250 mm, reversed-phase column with a 4-micron particle size (Phenomenex, Torrance, CA, USA). The mobile phase consisted of 50 mM sodium phosphate and acetonitrile (90%, 10% v/v) at a pH of 1.6, with a flowgradient of 0.75 ml/min for 0-8 min, 1.2 ml/min for 9-22 min and 0.75 ml/min for 0.5 min. The total run time was 23 min. Following the addition of internal standard (20 ng of 5, 6 dimethylbenzimidazole) plasma samples (0.75 mL) were extracted using a 3 cc Waters Oasis MAX solid-phase extraction cartridge. The plasma samples were pretreated with 0.8 ml of 4% phosphoric acid and loaded on to the conditioned SPE cartridge and rinsed with 2 ml of 4% NH 4 OH. The final elution was carried out with 2 ml of 4% NH 4 OH in methanol. The eluant was dried with a stream of nitrogen at 371C and reconstituted with 50 mL of mobile phase. F-ara-A standard and the 5, 6 dimethylbenzimidazole were obtained from Sigma-Aldrich (Milwaukee, WI, USA). The assay was linear in the range of 10-3000 ng/ mL. Assay accuracy, intraday and interday variability were 93.5-100.1%, 1.6-3.6% and 1.3-3.3%, respectively.
Pharmacokinetic analysis
For each patient, F-ara-A plasma concentration-time data were analyzed using noncompartmental methods (WinNonLin Professional 5.2). Area-under-the-curve (AUC (0ÀN) ) was estimated by the log/linear trapezoidal method as AUC (0Àt*) þ C(t*)/Ke, where C(t*) is the last concentration and Ke is the terminal first-order elimination rate constant. Ke was calculated from the slope of the log-linear portion of the plasma-concentration time curve using linear regression analysis. The terminal half-life was 0.693/Ke. Clearance was determined by dose/AUC (0ÀN) . Volume of distribution was estimated from terminal phase of the time-concentration data. C max was as the largest observed concentration. C min (trough) was the 24-h post dose concentration.
Statistical analysis
The primary objective of this study was to determine the relationship between F-ara-A systemic exposure and neutrophil engraftment. Secondary objectives were to evaluate the relationship between F-ara-A exposure and incidence of acute GVHD, TRM and OS. Neutrophil engraftment, acute GVHD, TRM and survival data were collected through the transplant database. GVHD was staged and graded according to the standard GVHD criteria based on clinical and pathological criteria. [22] [23] Day of neutrophil engraftment was defined as the first of the three consecutive measures of an ANC 4500 cells/mL in association with partial or complete chimerism by day 42 after transplantation. Graft failure was defined as survival without an ANC 4500 cells/mL at day 42 or autologous reconstitution. TRM was death without disease progression or relapse. For the survival analysis, death due to any cause was considered an event. Pharmacokinetic data were summarized by descriptive statistics. Normal renal function was defined as a CrCl 470 ml/min. Renal impairment was defined as CrClo 70 ml/min. 24 Probabilities and 95% confidence intervals of acute GVHD and TRM were calculated using the cumulative incidence function, whereas neutrophil engraftment and OS were calculated using the Kaplan-Meier method. Recursive partitioning regression analysis was used to determine optimal cutpoints for F-ara-A pharmacokinetic parameters (AUC (0ÀN) , C min , clearance and day zero ) towards clinical endpoint. Univariate analysis was carried out evaluating each pharmacokinetic parameter towards neutrophil engraftment, TRM at 30 days, 100 days, 6 and 12 months, and OS at 6 and 12 months, and time to acute GVHD to day 100. Univariate analysis was also carried out to evaluate clinical factors towards engraftment, TRM, OS and acute GVHD.
Cox's proportional hazards regression was used to model independent predictors of TRM at 6 months post-transplantation and included the following: F-ara-A AUC (0ÀN) , age, use of ATG in preparative regimen, recipient CMV status, donor source, comorbidity score 25, 26 , CrCl and acute GVHD grades II-IV.
Results
Patient characteristics are described in Table 1 Table 2 ). F-ara-A clearance was reduced by B25% in patients with decreased renal function. F-ara-A was detectable on the day of transplantation in all patients. F-ara-A dose adjusted AUC (0ÀN) was poorly correlated with CrCl (r 2 ¼ 0.22, Po0.01) and serum creatinine (r 2 ¼ 0.02, P ¼ 0.18).
Relationship between F-ara-A exposure and clinical outcomes Engraftment of donor cells. Primary neutrophil recovery occurred in 86% of patients at a median (range) of 11 days (1-38) following HCT. Graft failure occurred in 14 (16%) patients. In univariate analysis, no F-ara-A pharmacokinetic parameters were associated with the engraftment.
Acute GVHD. Cumulative incidences of grades II-IV and III-IV acute GVHD at day 100 were 50 and 17%, respectively. In univariate analysis, patients with an F-ara-A AUC (0ÀN) 46.5 mg h/mL had a significantly lower incidence of acute GVHD grades II-IV (14%) compared with those p6.5 mg h/mL (52%), P ¼ 0.04. No other F-ara-A pharmacokinetic parameters were associated with development of grades II-IV or III-IV acute GVHD.
TRM. The incidence of TRM at 6 months was 21% (95% confidence interval, 12-29%), occurring at a median of 1.5 months (range, 0.2-6.1) post-transplant (Figure 2a) . A total of 18 treatment-related deaths occurred due to multi-organ failure (n ¼ 8), the most common cause. Pulmonary and/or cardiac involvement was present in the majority of multiorgan failure deaths. The other causes of TRM included encephalopathy (n ¼ 3), infection (n ¼ 3), bleeding/thrombosis (n ¼ 3) and acute GVHD (n ¼ 1). In univariate analysis, patients with F-ara-A AUC (0ÀN) 46.5 mg h/mL had significantly higher cumulative incidence of TRM at 6 months (50%) compared with patients with F-ara-A AUC (0ÀN) p6.5 mg h/mL (15%), Po0.01 (Figure 2b) . The cause of death in the 7 patients with TRM and F-ara-A AUC (0ÀN) 46.5 mg h/mL included multi-organ failure (n ¼ 4), encephalopathy (n ¼ 1), infection (n ¼ 1) and bleeding/thrombosis (n ¼ 1). TRM at 6 months was also significantly higher in patients with F-ara-A clearance p12.5 L/h when compared with patients with an F-ara-A clearance 412.5 L/h (45% vs 12%, Po0.01). F-ara-A C min 480 ng/mL was associated with higher cumulative incidence of TRM at 6 months vs F-ara-A C min p80 ng/mL (64 vs 15%, Po0.01). F-ara-A concentrations on the day of transplantation p30 ng/mL were also associated with reduced TRM (12%) compared with patients with F-ara-A 430 ng/mL (53%), Po0.01. Of the 87 patients, 14 patients (16.1%) had F-ara-A AUC (0ÀN) 46.5 mg h/mL, 65 patients (74.7%) had troughs 480 ng/mL and 12 patients (10.44%) had an F-ara-A clearance o12.5 L/h. In all, 17 patients (14%) had F-ara-A concentrations X30 ng/mL on the day of stem cell infusion. F-ara-A pharmacokinetic parameters were also significant (Po0.01) towards TRM at 30 days, 100 days and 12 months (data not shown). In univariate analysis other clinical factors associated with higher risk of TRM at 6 months were ATG in the preparative regimen (30 vs 11%, P ¼ 0.02) and CrCl o70 mL/min compared with X70 mL/min (22 vs 2%, Po0.01).
The Cox regression analysis for F-ara-A AUC (0ÀN) is given in Table 3 . At 6 months after transplantation, the only independent predictor of TRM was F-ara-A AUC (0ÀN) . Patients with an F-ara-A AUC (0ÀN) 46.5 mg h/mL had a 4.56 greater risk of TRM than individuals with an AUC (0ÀN) p6.5 mg h/ml (P ¼ 0.02).
OS. Six-month OS was 71% (95% confidence interval: 60-80%) with 47 patients alive at a median of 12 months (range, 0.2-29.5) (Figure 3a) . The most frequent causes of death were disease relapse or progression (n ¼ 7), multiorgan failure (n ¼ 8), encephalopathy (n ¼ 3), infection (n ¼ 3), bleeding/thrombosis (n ¼ 3) and acute GVHD (n ¼ 1). In univariate analysis, patients with F-ara-A AUC (0ÀN) 46.5 mg h/mL had significantly lower OS (36%) at 6 months compared with patients with F-ara-A AUC (0ÀN) p6.5 mg h/mL (78%), Po0.01 (Figure 3b) . Similarly, OS at 6 months was lower in patients with F-ara-A clearance p12.5 L/h compared with clearance 412.5 L/h, 41 vs 81%, Po0.01, respectively. Elevated F-ara-A trough 480 ng/mL was associated with reduced OS 6 months post-transplantation (27 vs 76%), Po0.01. On the day of transplantation, patients with F-ara-A concentrations 430 ng/mL had significantly lower overall 6 month survival compared with patients with concentrations p30 ng/mL (41 vs 80% ), Po0.01. Pharmacokinetic parameters were also significant (Po0.01) towards OS at 12 month (data not shown).
Discussion
This is the first study to evaluate F-ara-A exposure and its relationship to stem cell engraftment, GVHD, TRM and OS in nonmyeloablative allogeneic HCT. We showed that F-ara-A exposure is highly variable with 5.7-fold difference in AUC in patients receiving fludarabine at 40 mg/m 2
. Our data also demonstrate that higher F-ara-A concentrations are associated with a greater risk of TRM and decreased survival. Finally, in preparative regimens that use 40 mg/m 2 of fludarabine, dose reductions greater than 20-25% should be considered in patients presenting for transplant with renal impairment.
The pharmacokinetic parameters in our study were consistent with those previously described in HCT patients. [19] [20] Studies outside the setting of HCT demonstrate F-ara-A clearance correlates with CrCl, with F-ara-A urinary excretion as high as 60% of the total administered dose. 13 In phase I trials of fludarabine a decline in renal function was associated with a decrease in total body clearance and volume of distribution. 18 As a result, fludarabine dose reductions of 20-25% are recommended by the manufacturer in patients with CrClo70 mL/min. 27 In our study, the 9 patients with pre-existing mild to moderate renal impairment (median CrCl 57.1 mL/min), despite receiving a 20-25% dose reduction, had higher plasma concentrations, reduced clearance of F-ara-A and longer half-life compared with patients not receiving dose reductions (median CrCl 85.9 mL/min). Therefore, dose reductions 420-25% may be required in HCT patients with mild to moderate renal impairment in preparative regimens that use fludarabine 40 mg/m 2 . Our analyses showed a strong relationship between highplasma F-ara-A exposure, TRM and OS. This is not surprising as higher exposure may result in greater tissue damage, and more potent and longer immunosuppression. A high comorbidity score and poor renal function may also be associated with greater TRM; however, they had no independent effect in the multivariate analyses. Patients also received CY and TBI. The metabolism and clearance of CY and its metabolites have been shown to be influenced by renal function and increased concentrations are associated with increased risk of toxicity in HCT. 28, 29 Given that multiple factors influence TRM, accumulation of F-ara-A plasma concentrations may be a surrogate marker of overall preparative regimen intensity.
Higher doses of fludarabine (40-100 mg/m 2 ) have been associated with delayed onset severe neurotoxicity including progressive multifocal leukoencephalopathy, coma and death. Early phase I/II trials conducted in relapsed leukemia estimated an 18% incidence of severe fludarabine neurotoxicity at these doses. [30] [31] In allogeneic HCT the incidence of neurotoxicity and risk factors are not well defined. Fludarabine has been suggested as a potential risk factor for neurotoxicity after umbilical cord transplantation. 32 Patients with elevated systemic plasma concentrations of F-ara-A may experience higher drug concentrations in the central nervous system. However, several confounding variables must be considered. Progressive multifocal leukoencephalopathy resulting from opportunistic infection with JC virus has been reported in CLL patients treated with fludarabine. [33] [34] [35] [36] More recently mycophenolate mofetil has been associated with case reports of progressive multifocal leukoencephalopathy. 37 Finally, all patients in this study were treated with CYA. Neurotoxicity, including posterior reversible leukoencephalopathy, may occur in upto 30% of patients receiving CYA. 38 Irreversible encephalopathy with the use of CYA in pediatric patients have also been reported. 39 We found no influence of F-ara-A pharmacokinetic measures on neutrophil engraftment. However, our engraftment rate was high, thereby reducing our ability to detect an effect. Studies in relapsed CLL patients comparing chemotherapy responders vs non-responders suggest that sufficient F-ara-A plasma concentrations are needed to maintain a minimum inhibitory F-ara-ATP concentration in tumor cells. 12 It is possible that the higher fludarabine dose, long terminal half-life, combined with the 5 day dosing regimen leads to sufficient intracellular F-ara-ATP needed for engraftment. It is interesting to note that detectable plasma F-ara-A was still present on the day of transplant in all patients. It is possible that patients receiving lower doses of fludarabine (25-30 mg/m 2 ) may not exceed these thresholds. Future studies in HCT should incorporate the evaluation of intracellular F-ara-ATP concentrations and the potential role of genetic polymorphisms involved in fludarabine pathway including cellular transporters, kinases and targets. [40] [41] [42] Engraftment is a complex process and is influenced by several factors including cell dose, donor source and mycophenolate mofetil exposure, and substantially larger sample sizes will be required to evaluate both genetic and non-genetic effects. 43 We found a strong association between higher plasma concentrations of fludarabine and increased risk of TRM and reduced OS after nonmyeloablative HCT. Whether these relationships hold true for other preparative regimens, especially those containing lower doses of fludarabine have yet to be established. Renal insufficiency led to higher concentrations of fludarabine and dose reductions are warranted to avoid excessive systemic exposure. Future studies are needed to further define the minimal level of F-ara-A exposure required for stem cell engraftment so that toxicity is minimized.
